Selexys' sickle cell disease drug is entering Phase II trial

08/20/2013 | Oklahoman (Oklahoma City), The

Selexys Pharmaceuticals has started patient enrollment for a midstage study of the experimental sickle cell disease drug SelG1. The trial, which will involve about 175 patients, will evaluate the drug's safety and efficacy with the goal of decreasing the frequency of sickle cell-related pain crises.

View Full Article in:

Oklahoman (Oklahoma City), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC